Literature DB >> 12791657

Memory B cells producing somatically mutated antiphospholipid antibodies are present in healthy individuals.

Patricia Lieby1, Anne Soley, Anne-Marie Knapp, Martine Cerutti, Jean-Marie Freyssinet, Jean-Louis Pasquali, Thierry Martin.   

Abstract

Antiphospholipid antibodies (aPLs) are associated with thrombosis and recurrent abortions during autoimmune pathologies, but they are also produced in healthy individuals and during infectious diseases. To analyze the possible links between physiologic and pathologic aPLs, it is of importance to characterize normal aPL production. We took advantage of the known tropism of Epstein-Barr virus (EBV) for B cells in general, and memory B cells in particular, during primary infectious mononucleosis (IMN) in 3 patients to get access to anticardiolipin (aCL)-producing B cells. Flow cytometry analysis of these cells showed that, depending on the patient, 10% to 60% of immunoglobulin M (IgM) aCL-producing B cells express the CD27 marker of memory B cells. Single cell sorting of aCL B cells, followed by single cell reverse transcription-polymerase chain reaction (RT-PCR) amplification of their immunoglobulin variable region genes, showed that some of these cells produce mutated forms of aCL antibodies, confirming their memory B-cell origin. Considering that, during primary IMN, EBV infects and expands already pre-existing memory B cells, we conclude that healthy individuals have a discrete pool of aCL memory cells able to produce mutated forms of antibodies. The implications of this new information are discussed in light of different hypotheses regarding the origin of aCL.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12791657     DOI: 10.1182/blood-2003-01-0180

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  Lepidopteran cells, an alternative for the production of recombinant antibodies?

Authors:  Martine Cérutti; Josée Golay
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

2.  Problems in using statistical analysis of replacement and silent mutations in antibody genes for determining antigen-driven affinity selection.

Authors:  Biplab Bose; Subrata Sinha
Journal:  Immunology       Date:  2005-10       Impact factor: 7.397

3.  Autoantigen, innate immunity, and T cells cooperate to break B cell tolerance during bacterial infection.

Authors:  Pauline Soulas; Anne Woods; Benoit Jaulhac; Anne-Marie Knapp; Jean-Louis Pasquali; Thierry Martin; Anne-Sophie Korganow
Journal:  J Clin Invest       Date:  2005-07-21       Impact factor: 14.808

Review 4.  Evasion and interactions of the humoral innate immune response in pathogen invasion, autoimmune disease, and cancer.

Authors:  Trisha A Rettig; Julie N Harbin; Adelaide Harrington; Leonie Dohmen; Sherry D Fleming
Journal:  Clin Immunol       Date:  2015-07-02       Impact factor: 3.969

5.  Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis.

Authors:  Nadine Müller-Calleja; Anne Hollerbach; Svenja Ritter; Denise G Pedrosa; Dennis Strand; Claudine Graf; Christoph Reinhardt; Susanne Strand; Philippe Poncelet; John H Griffin; Karl J Lackner; Wolfram Ruf
Journal:  Blood       Date:  2019-08-21       Impact factor: 22.113

6.  Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA.

Authors:  Charles C Chu; Rosa Catera; Katerina Hatzi; Xiao-Jie Yan; Lu Zhang; Xiao Bo Wang; Henry M Fales; Steven L Allen; Jonathan E Kolitz; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

7.  Acute myocardial infarction and transient elevated anticardiolipin antibody in a young adult with possible familial hypercholesterolemia: a case report : Anticardiolipin antibody and myocardial infarction.

Authors:  Xin Su; Aqian Wang; Hai Zhu; Hongling Su; Yichao Duan; Shanlian Wu; Min Zhang; Yan Huang; Xing Zhou; Yunshan Cao
Journal:  BMC Cardiovasc Disord       Date:  2019-06-27       Impact factor: 2.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.